Details of the Drug Combinations

General Information of This Drug (ID: DMAIL4L)

• Drug Name: Fludeoxyglucose F 18 (DMAIL4L)
• Synonyms: Fludeoxyglucose F18; Fludeoxyglucose (18F); Fludeoxyglucose F 18; 105851-17-0; FLUDEOXYGLUCOSE F-18; 18FDG; UNII-SBT3GBX27W; SBT3GBX27W; CHEBI:31617; 2-(Fluoro-18F)-2-deoxy-alpha-glucopyranose; alpha-D-Glucopyranose, 2-deoxy-2-(fluoro-18F)-; [18F]FDG; 2-Deoxy-2-fluoro-(sup 18)F-alpha-D-glucopyranose; Flucis; alpha-D-Glucopyranose, 2-deoxy-2-(fluoro-(sup 18)F)-; F-18 FDG; Fluorodeoxyglucose F 18; AC1L9OYT; 2-Deoxy-2-(fluoro-18f)-a-D-glucopyranose; Fludeoxyglucose F 18 (TN); SCHEMBL135994; Fludeoxyglucose F 18 (USP)

Indication

Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Fludeoxyglucose F 18 + Sunitinib	DCQY3BG	Sunitinib	Kidney Neoplasms	[2]
Fludeoxyglucose F 18 + Alovudine	DCTQSTB	Alovudine	Melanoma	[3]
Gemcitabine + Fludeoxyglucose F 18	DC44Q5V	Gemcitabine	Pancreatic Cancer	[4]
Uridine triacetate + Fludeoxyglucose F 18	DCNMK6Y	Uridine triacetate	Brain Imaging	[5]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT00537056) Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
• [3] ClinicalTrials.gov (NCT02891616) 18F-FLT PET Imaging in Patients With Advanced Melanoma
• [4] ClinicalTrials.gov (NCT01146054) Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
• [5] ClinicalTrials.gov (NCT04417998) Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction